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Aim: A double blind randomized cross over trial to compare the rate of decortication, safety
and efficacy of intrapleural instillation of Alteplase vs. Placebo in empyema and complicated
parapneumonic effusions (CPE).
Methods: Patients diagnosed with empyema or CPE and considered for surgery were given the
option to enter into this trial. Intrapleural instillation of the ‘Drug’ was given daily for three
days. Patient that failed the first arm of the trial were offered surgery or to cross over to
the second arm. Failure was documented if pleural effusions did not improve by 50% on CT
scans after three doses of the ‘Drug’ or if these effusions recurred within six weeks.
Results: One hundred and eight patients were evaluated and one hundred enrolled in the trial.
32 patients were excluded, 29 for noninfectious loculated effusions, two for protocol violation
and one for bleeding at chest tube site. There were 17 patients with empyema and 51 patients
with CPE. 58 of the 61 patients (26 crossed over) with empyema/CPE resolved with Alteplase
therapy compared to 4 of the 32 patients (one crossed over) treated with Placebo (p value
<0.001). None of the patients went to surgery. Adverse events with Alteplase therapy
compared to Placebo were not statistically significant, with chest pain and bleeding complica-
tions being the most common.University/Methodist Hospital, Midwest Pulmonary and Critical Care, 8552 Cass Street, Omaha,
(office), þ1 402 206 7372(mobile); fax: þ1 402 390 0899.
(G. Thommi), shehansix@cox.net (J.C. Shehan), jrmavsmom18@yahoo.com (K.L. Robison), michelle.
), lbackemeyer@yahoo.com (L.A. Backemeyer), mmcleay59@hotmail.com (M.T. McLeay).
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A double blind randomized cross over trial 717Conclusion: Intrapleural instillation of Alteplase is significantly more effective than Placebo in
patients with empyema and PPE (95% vs.12%). This study demonstrates it is safe and efficacious
with minimal adverse reactions.
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Approximately 1.3 million patients are hospitalized annu-
ally with pneumonia and in 36%e66% pleural effusions
occur. The majority of these effusions usually resolve with
antibiotics and standard medical therapy. However, 10%e
20% progress to an exudative stage that requires chest tube
drainage or surgical interventions. Mortality is increased as
these effusions evolve ranging from 7% to 33% in anaerobic
and pneumococcal pneumonia and in the elderly co morbid
patient.1e4 Delay in treatment and inadequate drainage of
these effusions can result in progressive sepsis, shock,
increase in morbidity and mortality. Exudative pleural
effusions in these patients have shown to have decreased
fibrinolytic activity, high TNF-alpha, high concentrations of
plasminogen activator inhibitor and decrease level of tissue
plasminogen activator.5,6 Simple chest tube drainage with
conventional medical treatment is often inadequate to
drain these effusions because of increased viscosity,
turbidity, and fibrin strand depositions. The rationale for
fibrinolytic therapy in empyema and CPE is to lyse locula-
tions, lyse fibrin deposits, decrease the viscosity of the fluid
and facilitate drainage.7e13Table 1 Patient characteristics.
CHF/ESRD/COPD 6 patients
CHF/COPD 11 patients
CHF/CMP 6
MPE 2 patients
CHF/RF 3
Recent DVT/PE 7
COPD (moderate to severe) 14
Postoperative 3 post CABG, 1 VATS,
1 Ca esophagus
Mechanical ventilation 2
Hemorrhagic pancreatitis 1
Lemierres syndrome, ARF 1
MSOF/ARF 1
Hemorrhagic pancreatitis 1 (with COPD, CHF)
Dementia/mental retardation 3
Cirrhosis/CHF 1
Severe pulmonary hypertension 1
(CREST syndrome)/COPD
Lung abscess 1 (same side of effusion)
Liver abscess 1 (same side of effusion)
ARF Acute renal failure, CHF congestive heart failure class 111/
1V, COPD chronic obstructive pulmonary disease (moderate to
severe), CRI chronic renal insufficiency, DVT deep vein throm-
bosis, ESRD end stage renal disease, MPE malignant pleural
effusion, MSOF multi system organ failure, PE pulmonary
embolus.Method
This was a double blind randomized Placebo controlled
cross over trial performed in the United States. Patients
with empyema or CPE considered for decortication or VATS
were given the option to enter into this trial. These
patients failed to resolve their effusions with chest tube
drainage and standard medical therapy. This trial was
approved by the FDA (IND #11415), IRB (#536, FWA
#00003377) at Methodist Hospital and enrolled through the
Clinicaltrials.gov (NCT #00468104). The primary end point
was a 40% reduction in surgical intervention between
Alteplase and Placebo groups. The secondary end point was
a 50% difference in resolution of dyspnea, sepsis syndrome
and pneumonia between the two groups. Patients were
excluded if they refused the trial, were below 18 years of
age, had active bleeding/known bleeding diathesis, had
recent cerebral vascular accident, had bronchopleural
fistula, had severe uncontrolled hypertension, had coagul-
opathy (INR > 4; PTT > 100, Platelet count <60,000), had
hypersensitivity to Alteplase, diagnosed with acute trau-
matic hemothorax, had pregnancy/positive pregnancy test,
refused standard medical therapy or to follow protocol.
Effusions were labeled empyema if pleural fluid glucose
level less than 60 mg/dl with normal or high blood glucose
values, if the Ph was less than 7.2, if the pleural fluid
culture was positive or if frank pus was noted. Effusions
were labeled CPE if the pleural fluid was an exudate and if
CT scan and ultrasound of the chest showed multiple
loculations with a pneumonic process. Chest tubes wereinserted if pleural effusions recurred after two thoracent-
esis within two weeks, if large loculated effusions were
present post thoracentesis, if pleural fluid culture was
positive or if pus was obtained. All patients were on broad-
spectrum antibiotics throughout the trial period. After
informed consent was obtained the hospital pharmacist
randomized patients by a fixed allocation randomization
process using a computer based random sequence genera-
tion. All investigators and data coordinators were blinded
and the pharmacist(s) had no contact with the patient, in
data collection and were not involved in the patient’s care.
Primarily 28 French catheters were utilized and connected
to a Pleuravac drainage system. However, smaller cathe-
ters, 14 to 16 French, were used in a few multi-loculated
effusions. Prior to instillation of the ‘Drug’, patients were
placed with the chest tube side up, the chest tube was
clamped and taken off suction. The chest tube position was
checked daily by physical examination and chest x-ray to
ensure that the chest tube was not dislodged. Alteplase
25 mg or Placebo in 100 mls of normal saline, divided in two
60 mls syringes, was instilled intrapleurally daily for three
days with an18 gauge needle through the Pleuravac tubing.
The chest tube was flushed with 50 mls saline and patients
were monitored in the same position for 20 min. The chest
tube was clamped for the first hour and suction was applied
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agreed to the second arm, the ‘Drug’ (Placebo or Alteplase)
not instilled in the first arm, was then instilled intra-
pleurally daily for three days. Adverse events were moni-
tored for at least 24 h. The principal investigator was the
only one assessing CXR or CT scans and the protocol allowed
up to six doses of the drug depending on CXR or CT
response. Failure to the first and second arm of the trial
was documented if the pleural fluid did not decrease by at
least 50% by CT scans on day four. Patients were offered
surgery if they failed the first and second arm of the trial.
PT/INR, PTT, thrombin time were performed before and 1 h
after each instillation. Fibrinogen levels, performed in later
half of the study, were obtained prior to and 1 h after
instillation. Chest X-rays were performed daily, two weeks
post-treatment and six weeks post-treatment. Baseline CT
scans of the chest was obtained initially, following the first
arm, the second arm and in all but one patient, eight to
twelve weeks later. Chest tube was removed when the
pleural fluid output was less than 150 mls in 24 h. SuccessFigure 1 Patient A: Initial CT scan of chest (top picture)
showing large left empyema with a chest tube in place. CT scan
of chest (lower figure) after 3 doses of intrapleural instillation
of Placebo showing no change.was determined at six weeks if CPE or empyema resolved
and did not reoccur.
Statistical analysis
AUnivariate analysis was done to identify possible predictors
of successful resolution of symptoms. The Chi-Square anal-
ysis was used to compare the percent successful and the
student’s t-test was used to compare averages between
those successful and those not. This study design raised the
question whether or not the order of treatment effected the
outcome. A logistics regression model was used to evaluate
the order of treatment. The dependent variable is success.
Independent variables included in the model were order of
treatment and treatment (i.e. Alteplase or Placebo).
Results
This trial was conducted over a five-year period. One
hundred and eight patients were evaluated for the trial ofFigure 2 Patient A. CT scan of chest after three doses of
Alteplase (top picture) showing significant clearing of
empyema and CT scan of chest three months after Alteplase
use (lower picture) showing complete resolution of empyema.
A double blind randomized cross over trial 719which one hundred entered the trial. Twenty-nine patients
were excluded as they did not meet criteria for CPE or
empyema. These loculated effusions were secondary to
congestive heart failure/cardiomyopathy (CHF/CMP), end
stage renal disease (ESRD) or malignant pleural effusion
(MPE). Two patients were excluded for protocol violation
and one for bleeding at chest tube site after the first dose
of Alteplase. Age ranged from 21 to 90 years with a mean of
64  15. Male to female ratio was 37:21. Sixty-eight
patients completed the trial, 17 patients with empyema
and 51 patients with CPE. These patients had multiple co
morbidities and patient’s characteristics are shown in
Table 1. Pleural fluid glucose levels were less than 60 mg/dl
in eleven patients, three were less than 30 mg/dl and five
were less than 10 mg/dl. The pH pleural fluid was less than
7.0 in one of the above patients. Pleural fluid culture was
positive in four patients (two MRSA, one Streptococcus and
one with Aspergillus) and two patients had frank pus. One
patient with presumed chronic empyema was excluded
from the study for persistent large pneumothorax despite
chest tube suction. Cardiothoracic surgeons declined thisFigure 3 Patient B. Initial CT scan of the chest (top picture)
showing large left CPE with adequate chest tube placement.
CT scan of chest (lower picture) showing worsening of left CPE
after three doses of Placebo.patient for decortication. All patients treated with three
doses of Alteplase had over 70% resolution of their effusions
and three patients that failed Alteplase therapy recurred
only after the chest tube was removed. Patients who failed
three doses of Placebo therapy showed no change or
increase in the amount of pleural effusions on CT scans.
(Figs. 1e4) Overall 58 of the 61 patients (95%; 26 cross over)
treated with Alteplase therapy resolved compared to four
of the 33 patients (12%; one cross over) treated with
Placebo (p value < 0.001). All 16 patients with empyema
(100%; four crossed over) treated with Alteplase resolved
compared to none of the five patients (0%) treated with
placebo (p value < 0.001). Alteplase was effective in 42 of
the 45 patients with CPE (93%; 22 patients crossed over)
compared to four of the 28 patients (13%; one patient
crossed over) treated with Placebo (p value < 0.001; Chart
1, Figs. 1e4). Three patients with CPE that failed AlteplaseFigure 4 Patient B. CT scan of chest (top picture) after 3
doses of Alteplase showing significant clearing of the left CPE
but note residual effusion/infiltrate. CT scan of chest (lower
picture) 3 months after Alteplase use showing complete
clearing of the left CPE.
Assessed for eligibility
108 patients 
Excluded  (n= 8)
Refused to participate -2 patients
physician opted against the trial 
2 patients
inadvertent chest tube removal 
               3 patients
bleeding complications pre trial
1 patient
Empyema/PPE patients: 68
          35 received Alteplase
32 received Placebo
1 discarded trapped lung
Discarded
29  patients noninfectious
2 protocol violation
1-bleeding at chest tube site
Results
Enrolled
Randomized
100 patients
ALTEPLASE success
Empyema: 12/12; 100%
PPE: 20/23; 87%
Cross over to 2nd arm: Alteplase
Empyema:  4/4 -- success: 100 % 
        refused : 1 patient
PPE:  22/22 patients --success:  100 %
          refused:  2 patients
First arm of the trial
100 patients
Responded to Alteplase: 32
Responded to Placebo:  3 
Crosa over to 2nd arm: Placebo
Empyema:  none
PPE : 0/1 --success: 0%  
refused: 2 patients
PLACEBO success
 Empyema:  0/5; 0%
PPE: 4/28 (14%)
All patients refused surgery
Chart 1 Alteplase/Placebo-Flowchart.
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moderate, did not require thoracentesis, chest tube
placements or surgical intervention for up to six months.
These patients refused surgery and two of them were in
New York Heart Association class III to IV CHF. Twenty -five
patients that failed Placebo therapy refused surgical
intervention and three of them refused to be crossed over.
Small bore catheters in two patients with empyema kept
getting blocked and kinked, required frequent flushing and
one patient needed four doses of Alteplase. The secondary
end points could not be measured as all but one patient
that failed the first arm were crossed over to the second
arm on day four.
Pleural fluid drainagemeasured dailywas 100mlse300mls
more with Alteplase than Placebo therapy in a majority of
patients and in both groups the pleural fluid drainage
decreasedwith subsequent instillations. The time from initial
presentation to initiation of therapywas from twodays to two
weeks in empyema and CPE patients. The order of treatment
was not significant (pZ 0.602). Overall chest pain for Alte-
plase and for placebo was statistically not significant (p
valueZ 0.952). Other adverse events showed no statistical
difference between Alteplase and Placebo. No abnormalities
in coagulation obtained pre and one-hour post-treatment,
were noted either with Alteplase or Placebo use. CRP (C
reactiveprotein) valuesmeasureddaily didnotcorrelatewithefficacy either with Alteplase or Placebo therapy. No signifi-
cant change in WBC and platelet counts was noted with
Alteplase or Placebo use.
Two of the eight patients that did not enter the trial
were sent directly for decortication and both needed
mechanical ventilation for a few days. One patient with
empyema was not enrolled for bleeding complications
secondary to sepsis and necrotizing pneumonia. This
patient underwent decortication requiring multiple chest
tubes for bronchopleural fistulas resulting in a prolonged
hospital course. Two patients refused to enter the trial (one
post decortication) and three patients that agreed to the
trial had their chest tubes discontinued inadvertently. One
of these patients that had his chest tube removed inad-
vertently post VATS continued to have persistent loculated
effusions/infiltrate six months later.Complications
Two patients had blood loss with Alteplase therapy (not
statistically significant p < 0.952). One patient bled at the
chest tube site immediately after Alteplase instillation,
required transfusion and was taken off the trial. Hypoten-
sion and anemia occurred several hours after the second
dose of Alteplase therapy in the second patient. This
A double blind randomized cross over trial 721patient also required transfusion and was one of the six
bloody effusions treated with Alteplase. Two patients in the
Placebo arm had progressive sepsis and dyspnea (not
statistically significant p < 0.952). Chest pain in the Alte-
plase group was moderate in four patients and mild in one
patient compared to four patients in the Placebo group
with mild chest pain. (not statistically significant;
p < 0.354). No other adverse events or deaths were
observed related to the Alteplase or Placebo therapy.Photograph 1 Large debri noted in chest tubes in different
patients post Alteplase instillation (open arrows). These easily
obstruct smaller chest tube catheters.Discussion
This is the first study to our knowledge, comparing Alteplase
to Placebo in a randomized double blind trial in patients
with empyema or CPE. The primary finding in this study
showed Alteplase to be significantly more effective than
Placebo in reducing surgical interventions in patients with
empyema and CPE (95% vs.12%). Secondary end points and
length of stay were not measured as all but one patient was
crossed over on day four. The ideal fibrinolytic agent for
loculated pleural effusions should have high fibrin affinity
and binding, a short half-life, high fibrin selectivity and
specificity and can be administered by a non-invasive
method. Alteplase has such properties with high fibrin
affinity and fibrin selectivity with a half-life of four to
8 min.14,15 However, SK has low fibrin affinity and fibrin
selectivity, has little effect on pus viscosity and may simply
work by breaking down loculations mechanically.16,17 Rah-
man et al concluded that Alteplase is effective only when
combined with DNase.18 However these investigators used
chest radiographs and not chest CT to determine the
response to therapy. Chest Radiographs, including decubitus
views, are inaccurate in detecting and quantifying pleural
effusions and cannot differentiate associated pneumonic
processes, elevated diaphragm, lung abscess and even
a mass.19e22 The dose of Alteplase used in Rahman’ study
(10 mg vs. 25 mg) may be insufficient and could have
contributed to its failure.12,13,23,24 However, if surgical
intervention was the primary end point there was very little
difference between Alteplase and Alteplase/DNase group
(3/48 vs. 2/48). Moreover, surgical referrals were actually
increased in the DNase group compared to the Placebo
group (18/46 vs. 8/51) implying that DNase may have
minimal or no fibrinolytic activity. Several studies have
shown Alteplase to be effective as a single agent in patients
with empyema or CPE in adults and children.12,13,24e27
Prior to intrapleural fibrinolytic therapy, patients with
empyema and CPE that failed chest tube placement and
antibiotics therapy usually required surgical intervention.
In elderly patients with multiple co morbidities mortality
can be up to 5% in Video Assisted Thoracic Surgery (VATS)
and 10% with decortication. Recurrence of empyema of up
to 2.6% occurs in decortications or VATS. Complications of
VATS or decortications include bleeding, infection, intol-
erance to single lung ventilation, re-expansion pulmonary
edema, prolonged ventilatory support, intercostal
neuralgia, multiple chest tube placements for persistent air
leaks and bronchopleural fistulas.28,29 Post operative pain
control can be a major problem resulting in over sedation,
atelectasis, pneumonia, urinary retention, hypoxemia and
worsening respiratory depression. Nonsurgical candidatesor those who refused surgery often have multiple image-
guided catheters placed by interventional radiologists (IR)
at different locations. While there are case reports of
success with this method, adjusting chest tubes every two
to three days under CT guidance have not been proven by
controlled trials.30 Multiple chest tubes placements and
adjustments under CT scan guidance result in pain control
problems, increase cost, increase lung injury and prolong
hospital stay. In contrast, patients in the current study
treated with Alteplase did not require mechanical
Figure 5 Initial CT scan of chest (top left) and CT scan of chest after three doses of Alteplase (top right) showing loculated fluid
collection but overall improvement of more than 50%. Note that the pneumonia/consolidation shows no change. CT scan of chest
six weeks later (bottom picture) showing complete resolution of CPE and pneumonia.
722 G. Thommi et al.ventilation, had no bronchopleural fistulas or problems with
persistent air leaks, did not have respiratory distress or
depression and had no problems with pain control.
Rahman et al reported no change in clinical outcomes
using different size chest tubes. However, placements of
these chest tubes were not randomized and larger chest
tubes were placed for more purulent effusions. Moreover,
chest radiographs and not chest CT scans were performed
to document outcome.31 The size of chest tube catheters,
in our experience, is critical to prevent failure as catheters
less than 20 cm French require flushing several times daily,
tend to loop and kink frequently and have a failure rate of
up to 20%.30,32e34 Large debris occurs with Alteplase use,
especially in empyema and CPE, causing smaller chest tube
catheters to get obstructed. (Photograph 1) Significant pain
and catheter blockage can also be a problem if these
catheters are inserted through large muscle groups.
Bleeding complications has been a primary concern for
intrapleural instillation of Alteplase and has prevented its
use. In the current study the risk of bleeding was small,
there was no evidence of systemic absorption of Alteplase
and bleeding was not seen in any other site other than the
chest.35 Bleeding complications can be avoided if Alteplase
is not used when the INR > 4, PTT above 50, Platelet
<50,000 and if bleeding time or platelet function assay is
abnormal. Following a significant bleed in the first patient,
subsequent instillations of the ‘Drug’ were performed with
the chest tube side up for 20 min to prevent the ‘Drug’ from
coming in contact with the chest wall incision. Bleeding
complications did not occur when Lovenox 40 mg or heparin10,000 units was administered subcutaneously with intra-
pleural instillation of Alteplase.
Residual pleural effusions similar to postsurgical changes
were common after the third dose of Alteplase but these
resolve in six to eight weeks and should not be considered
Alteplase failure. Furthermore, associated consolidation
with these effusions may take up to 12 weeks to resolve,
emphasizing the importance of differentiating an effusion
from consolidated lung by CT scans (Fig. 5). The pleural
space appears to get ‘sealed’ after the first or second dose
of Alteplase therapy in some empyema patients and
subsequent administration becomes difficult and painful.
Further instillation of Alteplase was discontinued and
follow up of these patients in six weeks showed compete
resolution of their empyema.
Conclusion
Alteplase therapy was significantly more effective than
Placebo therapy (95% vs.12%; p value<0.001) in empyemaand
CPE. Three doses of Alteplase instillation prevent surgical
interventions with its associated morbidity, mortality and
higher costs. Intrapleural instillation of Alteplase is easy to
administer, safe, efficacious,andhasminimal adverseeffects.
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